More cancer survivors prescribed 5 or more unique medications, including those with abuse potential
After a median 20 years of follow-up, heart failure not associated with cancer incidence
Majority say they want to know about even minor consequences of cancer drug substitutions
Structure demonstrated to be part of the submucosa, supported by network of thick collagen bundles
Fatigability and poor endurance significantly higher in older adults with cancer history
Strongest associations found for lung and colorectal cancer
No evidence for circulating tumor DNA assays in early-stage cancer, residual disease detection
Inverse correlation for plasma 25-hydroxyvitamin D concentration with total cancer, liver cancer
Better reimbursement at hospital outpatient depts, even though drug-level costs lower in doctor's office
Fibrinogen, von Willebrand factor are potential markers of mortality in cancer survivors.
Reductions seen in fatigue symptom severity and fatigue-related quality of life disruption
Many young adult cancer survivors do not follow up properly, independent of disease type or insurance.
10 increase in proportions of ultra-processed foods tied to 10 higher breast and overall cancer risk
Model includes 4 prognostic categories with clinical consequences to predict median survival.
Risk scores summarizing 8 diseases, markers tied to cancer risk in dose-response manner
Increasing trend seen for some lethal cancers, with up to 5% increase for liver, pancreas, lung CAs.
Persistent symptoms, comorbidities, leisure-time physical activity, financial challenges deemed key factors
Continuous drop in combined cancer death rate from 1991 to 2015, resulting in 2,378,600 fewer death.
Higher mortality for heart transplant patients with de novo solid malignancy than those without malignancy.
Durable survival, response rates rarely recognized as significant by current oncology value frameworks.
Most patients with cancer, autoimmune disease have improvement in events without discontinuing therapy.
Across cancers, higher costs tied to higher rates of oral prescription abandonment, delayed initiation.
Certain chemotherapies might shorten telomeres and alter microRNA.
Patients with end-stage renal disease (ESRD) have a 6-fold and 4.4-fold increased risk of kidney cancer and urothelial cancers, respectively, than individuals without ESRD.
ERK1/2 kinase inhibitor, ulixertinib, was used to treat cancer patients with MAPK mutant solid tumors.
Male patients with mCRPC and seizure risk factors did not have increased seizure incidents when taking Enzalutamide.
Cancer survival was greatly skewed toward patients with Medicare or private insurance.
About 45.1% of cancer deaths and 42% of all incident cancers are linked to modifiable risk factors.
Comorbidity may be higher in American Indians and Native Alaskans than in non-Hispanic white cancer patients.
The combined effects of high BMI and diabetes resulted in 5.6% of all incident cancers in 2012.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)